MedPath

Amygdala and dLPFC MRI-TIS for Depression in Adolescents

Not Applicable
Recruiting
Conditions
Major Depressive Disorder
Interventions
Device: Nervio-X
Registration Number
NCT06452849
Lead Sponsor
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Brief Summary

The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in adolescent depressive disorders.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Participants must be aged between 14 and 18, with no gender restrictions;
  • A diagnosis of depression made by the study physician based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
  • HAMD-17 score of 17 or higher;
  • Participants must not have changed their antidepressant medication regimen from 30 days prior to signing the informed consent form through the duration of the experiment;
  • Eligible individuals or their authorized representatives must demonstrate, as assessed by the study physician, a comprehensive understanding of the study's objectives and procedures, be capable of adhering to the requirements set forth in the study protocol, and provide their signature on the informed consent form.
Exclusion Criteria
  • Eligible participants must not have a history of psychiatric or neurological disorders, as judged by the investigator, which may impact the evaluation of the study's efficacy;
  • Participants must not have a history of seizures or prior episodes of epilepsy;
  • The presence of metallic foreign objects within the cranial structure or metallic cardiac implants;
  • Participants must not have a diagnosis of organic brain disease, nor a history of significant cranial trauma or neurosurgical intervention;
  • Participants received electroconvulsive therapy or other physical therapies (such as transcranial magnetic stimulation therapy); The researcher evaluated the individual's mental state and determined it to present a significant risk of suicidal ideation or behavior;
  • Pregnant or breastfeeding;
  • Participants who are concurrently engaged in other clinical interventional trials;
  • Participants presenting with other circumstances that the investigator deems unsuitable for the intervention being studied

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
dLPFC TINervio-XL_dLPFC TI Temporal Interference (TI) stimulation with 10 frequency difference, 20 minutes per day for 5 days.
Amygdala TINervio-XRight amygdala Temporal Interference (TI) stimulation with 100 frequency difference, 20 minutes per day for 5 days.
Primary Outcome Measures
NameTimeMethod
MADRSBaseline, after treatment, 1 week, 4 weeks and 8 weeks
PHQ-ABaseline, after treatment, 1 week, 4 weeks and 8 weeks
SF-36Baseline and 8 weeks
SHAPSBaseline, 4 weeks and 8 weeks
PSQIBaseline, 4 weeks and 8 weeks
WHOQOL-BREFBaseline and 8 weeks
HAMD-17Baseline, after treatment, 1 week, 4 weeks and 8 weeks
HAMABaseline, after treatment, 1 week, 4 weeks and 8 weeks
GAD-7Baseline, after treatment, 1 week, 4 weeks and 8 weeks
ARIBaseline and 8 weeks
OSIBaseline, 4 weeks and 8 weeks

For use when the patient exhibits self-harming behavior

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shanghai Pudong New Area Mental Health Center

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath